title: Receptor change-clinicopathologic analysis of matched pairs of primary and cerebral metastatic breast cancer.
abstract: OBJECTIVE
  A challenge in the management of breast cancer is development of brain metastases (BM) with limited survival. In primary breast cancer, ER/PR/HER2 are important prognostic markers and are important for making effective treatment decisions. Changes in immunohistochemical markers of metastases are with unclear clinical significance, and mechanisms of resistance to endocrine therapy are an additional challenge. The aim of this retrospective study is to detect changes in immunohistochemical markers of primary and BM and to recognize if receptor change has prognostic impact.
  
  
  METHODS
  Twenty-four consecutive primary breast cancer patients who developed BM and got surgical resection of BM were enrolled. Matched pair analyses of primary and BM were done with evaluation by immunostaining (ER/PR/HER2).
  
  
  RESULTS
  A small tumor size, ductal histology and HER2+ tumors were associated with BM. Loss of ER/PR receptor positivity was observed in BM compared to primary (ER: 50.0 %/22.7 %; p = 0.004; PR: 45.8 %/9.1 %; p = n.s), respectively, and almost no change in HER2 status (>80 %; p = 0.012). Patients with ER-/PR-negative or HER2-positive primary had shorter time to recurrence than ER-/PR-positive and HER2-negative patients. Receptor change has negative prognostic impact.
  
  
  CONCLUSIONS
  With the observed loss of receptor positivity, therapeutic options are diminished. Identification of patients with a high risk for BM is warranted to evaluate preventive strategies.
authors.affiliation: Department of Gynecology and Obstetrics, University Tübingen, Calwer Str. 7, 72070, Tübingen, Germany, cornelia.bachmann@med.uni-tuebingen.de.
authors.forename: C
authors.initials: C
authors.lastname: Bachmann
authors.forename: E M
authors.initials: EM
authors.lastname: Grischke
authors.forename: A
authors.initials: A
authors.lastname: Staebler
authors.forename: J
authors.initials: J
authors.lastname: Schittenhelm
authors.forename: D
authors.initials: D
authors.lastname: Wallwiener
mesh_terms: D000328:Adult; D000368:Aged; D001932:Brain Neoplasms / Q000378:metabolism* / Q000556:secondary*; D001943:Breast Neoplasms / Q000378:metabolism / Q000473:pathology; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D011960:Receptors, Estrogen / Q000378:metabolism*; D011980:Receptors, Progesterone / Q000378:metabolism*; D012189:Retrospective Studies; D064726:Triple Negative Breast Neoplasms / Q000378:metabolism* / Q000473:pathology*
chemical_list: D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; C508053:ERBB2 protein, human
references.citation: Oncologist. 2010;15(11):1164-8
references.pmid: 21041379
references.citation: Crit Rev Oncol Hematol. 2010 May;74(2):73-8
references.pmid: 19481955
references.citation: Cancer Treat Rev. 2013 Nov;39(7):720-7
references.pmid: 23481218
references.citation: Breast Cancer Res Treat. 2008 May;109(2):231-9
references.pmid: 17638068
references.citation: J Neurooncol. 2008 Nov;90(2):223-8
references.pmid: 18648908
references.citation: Cancer. 2011 Apr 15;117(8):1602-11
references.pmid: 21472708
references.citation: J Clin Oncol. 2009 Nov 1;27(31):5278-86
references.pmid: 19770385
references.citation: Cancer. 2011 May 1;117(9):1837-46
references.pmid: 21509760
references.citation: J Cancer Res Clin Oncol. 2013 Apr;139(4):551-6
references.pmid: 23224376
references.citation: N Engl J Med. 2005 Oct 20;353(16):1673-84
references.pmid: 16236738
references.citation: Appl Immunohistochem Mol Morphol. 2003 Sep;11(3):214-21
references.pmid: 12966347
references.citation: Mod Pathol. 2007 Aug;20(8):864-70
references.pmid: 17541441
references.citation: J Clin Oncol. 2002 Oct 1;20(19):4130-3
references.pmid: 12351617
references.citation: J Clin Oncol. 2006 Dec 20;24(36):5658-63
references.pmid: 17102066
references.citation: Int J Cancer. 1991 Nov 11;49(5):650-5
references.pmid: 1682277
references.citation: Ann Oncol. 2009 Sep;20(9):1499-1504
references.pmid: 19299408
references.citation: Lancet. 2007 Jan 6;369(9555):29-36
references.pmid: 17208639
references.citation: Ann Oncol. 2011 Jul;22(7):1571-1581
references.pmid: 21059640
references.citation: Anticancer Res. 2009 May;29(5):1557-62
references.pmid: 19443366
references.citation: J Neurooncol. 2007 Dec;85(3):311-7
references.pmid: 17557136
references.citation: J Clin Oncol. 2012 Feb 20;30(6):593-9
references.pmid: 22124109
references.citation: Clin Breast Cancer. 2003 Jun;4(2):114-9
references.pmid: 12864939
references.citation: Endocr Relat Cancer. 2005 Dec;12(4):721-47
references.pmid: 16322319
references.citation: Ann Oncol. 2006 Jun;17(6):935-44
references.pmid: 16603601
references.citation: J Clin Oncol. 2005 Jul 1;23(19):4265-74
references.pmid: 15911866
references.citation: J Clin Oncol. 2010 Jan 1;28(1):92-8
references.pmid: 19933921
references.citation: Ann Oncol. 2004 Nov;15(11):1640-4
references.pmid: 15520065
references.citation: Ann Oncol. 2009 Apr;20(4):621-7
references.pmid: 19150943
references.citation: Ann Oncol. 2008 Jul;19(7):1242-1248
references.pmid: 18334512
references.citation: Genet Res Int. 2011;2011:219189
references.pmid: 22567347
references.citation: Arch Pathol Lab Med. 2007;131(1):18-43
references.pmid: 19548375
references.citation: Arch Pathol Lab Med. 2003 Nov;127(11):1451-7
references.pmid: 14567724
references.citation: Expert Rev Anticancer Ther. 2013 Feb;13(2):143-7
references.pmid: 23406555
references.citation: Cancer. 2003 Dec 15;98(12):2547-53
references.pmid: 14669272
references.citation: Am J Clin Pathol. 2010 Mar;133(3):416-29
references.pmid: 20154280
references.citation: Am J Clin Oncol. 2008 Jun;31(3):250-4
references.pmid: 18525303
references.citation: N Engl J Med. 2001 Mar 15;344(11):783-92
references.pmid: 11248153
references.citation: Breast Cancer Res. 2010;12(4):R46
references.pmid: 20604919
references.citation: Ann Oncol. 2009 Jan;20(1):56-62
references.pmid: 18664558